Ivacaftor (hydrate)
Modify Date: 2025-08-25 07:56:39
Ivacaftor (hydrate) structure
|
Common Name | Ivacaftor (hydrate) | ||
|---|---|---|---|---|
| CAS Number | 1134822-07-3 | Molecular Weight | 410.50600 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H30N2O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ivacaftor (hydrate)Ivacaftor hydrate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment. |
| Name | N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.H2O |
|---|---|
| Synonym | More Synonyms |
| Description | Ivacaftor hydrate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment. |
|---|---|
| Related Catalog | |
| In Vitro | Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants[1]. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells[2]. Ivacaftor shows no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs[3]. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM[4]. |
| In Vivo | Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat[3]. |
| References |
| Molecular Formula | C24H30N2O4 |
|---|---|
| Molecular Weight | 410.50600 |
| Exact Mass | 410.22100 |
| PSA | 91.42000 |
| LogP | 5.08970 |
| Storage condition | 2-8℃ |
| Ivacaftor (hydrate) |